Volume 7 Number 11/12 November/December 2006
25 December 2006. Related: Editorial.
2006
BHIVA Autumn conference, 13-14 October 2006, London
8 December 2006. Related: Conference reports.
New i-Base book: Why we must provide HIV treatment information
7 December 2006. Related: Editorial.
Causes of death in the UK: results from BHIVA audit
7 December 2006. Related: Conference reports.
8th International Congress on Drug Therapy in HIV Infection, 12-16 November 2006, Glasgow
7 December 2006. Related: Conference reports.
Higher doses of ribavirin increases response rate to HCV treatment in coinfected patients: results from PRESCO study
6 December 2006. Related: Conference reports, Hepatitis coinfection.
NNRTI levels high in HCV co-Infected patients with cirrhosis
6 December 2006. Related: Conference reports, Hepatitis coinfection.
Viral load blips in children from the CHIPS cohort
6 December 2006. Related: Conference reports.
Multi-drug resistance in vertically infected children
6 December 2006. Related: Conference reports, Paediatric care, Drug resistance.
Wide disparity in switch to second-line therapy among children in CHIPS cohort
6 December 2006. Related: Conference reports, Paediatric care.
Explanation for failure of TMC-125 (etravirine) in TMC227 study
6 December 2006. Related: Conference reports, Antiretrovirals.
Saquinavir/r vs lopinavir/r: interim results from the Gemini study
6 December 2006. Related: Conference reports, Antiretrovirals.
d4T associated with significantly increased risk of type-2 diabetes mellitus
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Drug interactions with darunavir (TMC-114)
6 December 2006. Related: Conference reports, PK and drug interactions.
Drug interactions with etravirine (TMC-125)
6 December 2006. Related: Conference reports, PK and drug interactions.
Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Community meeting on criminalisation of HIV transmission: jailing people for passing on HIV may threaten public health
6 December 2006. Related: Conference reports.
TMC 114 recommended for conditional approval in Europe
6 December 2006. Related: Antiretrovirals.
Atazanavir 300mg capsule approved in US
6 December 2006. Related: Antiretrovirals.
Clinton price for new paediatric treatment
6 December 2006. Related: Treatment access.
Indian generic heat-stable ritonavir
6 December 2006. Related: Treatment access.
Generic FDC of efavirenz/tenofovir/FTC launched by Cipla
6 December 2006. Related: Treatment access.
Compulsory license for efavirenz in Thailand
6 December 2006. Related: Treatment access.
WHO EURO releases European clinical protocols for HIV/AIDS care and the report of the consultation on criminalisation of HIV/AIDS (2006)
6 December 2006. Related: Guidelines.
US adult treatment guidelines updated (Oct 2006)
6 December 2006. Related: Guidelines.
US perinatal guidelines updated (2006)
6 December 2006. Related: Pregnancy, Guidelines.
US guidelines for the use of antiretroviral agents in paediatric HIV infection revised (2006)
6 December 2006. Related: Paediatric care, Guidelines.
HIV and poverty in the UK
6 December 2006. Related: On the web.
PRN notebook –October 2006
6 December 2006. Related: On the web.
HIV inSite updates
6 December 2006. Related: On the web.
Management of metabolic and morphologic sequelae of HIV
6 December 2006. Related: On the web.
IAPAC European Sessions 2006
6 December 2006. Related: On the web.
IAVI Vax news
6 December 2006. Related: On the web.
Volume 7 Number 11/12 November/December 2006 PDF
1 December 2006. Related: PDFs.
Volume 7 Number 10 October 2006
25 October 2006. Related: Editorial.
New i-Base Book: Why we must provide HIV treatment information
21 October 2006. Related: Editorial.
8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 23-26 September 2006, San Francisco
16 October 2006. Related: Conference reports.
The role of the metabolic syndrome in HIV
15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Leptin reduces visceral abdominal tissue (VAT) without reducing limb fat
8 October 2006. Related: Conference reports.
Adipose tissue morphology improved after treatment discontinuation
8 October 2006. Related: Conference reports.
Incidence of lipodystrophy in Rwanda
8 October 2006. Related: Conference reports.
46th Interscience Conference on Antiretroviral Agents and Chemotherapy (ICAAC), 27-30 September 2006, San Francisco
7 October 2006. Related: Conference reports.
MK-0518 demonstrates potent efficacy in patients with triple-class resistant virus: 24 week results
7 October 2006. Related: Conference reports, Drug resistance.
Lipid profile of integrase inhibitor MK-0518: 24 week results compared to efavirenz in treatment naive patients
7 October 2006. Related: Conference reports, Antiretrovirals.
Cell studies predict cross-resistance among integrase inhibitors
7 October 2006. Related: Conference reports, Drug resistance.
HIV may use different coreceptors in blood and brain
7 October 2006. Related: Conference reports, Basic science and immunology.
Critical interactions between darunavir (TMC114), lopinavir, Viagra, and oral contraceptives
7 October 2006. Related: Conference reports, PK and drug interactions.
NRTI elvucitabine active against HIV in a 7-day monotherapy study
7 October 2006. Related: Conference reports, Antiretrovirals.
Efavirenz/tenofovir fails as 2-drug maintenance regimen
7 October 2006. Related: Conference reports, Antiretrovirals.
Nucleoside inhibitor MK-0608 mediates suppression of HCV replication for >30 days in chronically infected chimpanzees
7 October 2006. Related: Conference reports, Hepatitis coinfection.
Report from the 10th Annual UK Resistance Meeting, 21 September 2006, London
7 October 2006. Related: Conference reports, Drug resistance.
Further reports from XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada
7 October 2006. Related: Conference reports.
Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV positive women in Lusaka, Zambia
7 October 2006. Related: Conference reports, Women's health, Cancer and HIV.
Effect of herpes simplex therapy on genital and plasma HIV viral load
7 October 2006. Related: Conference reports, Women's health.
Maternal health and prevention of mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
18-month effectiveness of short-course perinatal antiretroviral regimens combined to infant-feeding interventions for PMTCT in DITRAME PLUS ANRS 1201/1202 2001-2005
7 October 2006. Related: Conference reports, Pregnancy.
HIV prevalence rates amongst 6 week old infants in South Africa: the case for universal screening at immunisation clinics
7 October 2006. Related: Conference reports, Pregnancy.
Maternal illness during pregnancy is associated with In utero mother to child transmission
7 October 2006. Related: Conference reports, Pregnancy.
Extensively drug resistant TB (XTB) in South Africa
7 October 2006. Related: Conference reports, TB coinfection.
Early access programme for MK-0518 integrase inhibitor
7 October 2006. Related: Antiretrovirals.
Etravirine (TMC-125) available on named patient programme in the UK
7 October 2006. Related: Antiretrovirals.
Fixed dose combination (FDC) of tenofovir/FTC/efavirenz (Atripla) filed in EU
7 October 2006. Related: Antiretrovirals.
Tipranavir available in Scotland – almost one year after EU approval
7 October 2006. Related: Antiretrovirals.